Sage Therapeutics
Sage, Biogen’s zuranolone looks approvable, but will it sell?
Phil Taylor
Biogen, depression, Psychiatry, Sage Therapeutics, zuranolone
0 Comment
Biogen, Sage prep 2022 filing for depression drug zuranolone
Phil Taylor
Biogen, depression, fda, Psychiatry, Sage Therapeutics, zuranolone
0 Comment
Sage/Biogen’s zuranolone works in depression, but maybe not enough
Phil Taylor
Biogen, central nervous system, depression, Psychiatry, Sage Therapeutics, zuranolone
0 Comment
Biogen bulks up pipeline with Sage drugs in $3bn deal
Phil Taylor
Biogen, depression, essential tremor, licensing, neurology, Psychiatry, Sage Therapeutics
0 Comment
R&D/ Views & Analysis/ Views and analysis
R&D roundup – Sage impresses at JP Morgan
George Underwood
AbbVie, Biogen, J&J, JP Morgan, Sage Therapeutics
0 Comment